Last Updated: 13 Nov 2024
Executive Summary
Entera Bio Ltd. (ENTX) is a clinical-stage biopharmaceutical company focused on developing orally administered large molecule therapies for unmet medical needs. The company has a market capitalization of $61.75 million and is currently trading at $1.67 per share.
Company Overview
Entera Bio is headquartered in Jerusalem, Israel, and was founded in 2006. The company's lead product candidate, EB613, is an oral formulation of human growth hormone (hGH) for the treatment of growth hormone deficiency (GHD). EB613 is currently in Phase 2 clinical trials.
Fundamental Analysis
Entera Bio's financial performance has been mixed in recent years. The company reported a net loss of $9.16 million in 2023, and its revenue for the year was $99,000. The company's operating margin was -71.93%, and its return on assets was -0.706%.
Entera Bio's balance sheet is relatively strong. The company has $18.2 million in cash and equivalents and no debt. The company's book value is $0.182 per share.
Technical Analysis
Entera Bio's stock price has been in a downtrend since early 2023. The stock is currently trading below its 50-day and 200-day moving averages. The Relative Strength Index (RSI) is at 30.08, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for Entera Bio is mixed. The company's stock price is currently trading at a significant discount to its analyst target price of $10.00. However, the company's financial performance has been weak in recent quarters, and the stock is trading below its moving averages.
Long Term Outlook
The long-term outlook for Entera Bio is more positive. The company's lead product candidate, EB613, has the potential to be a blockbuster drug. If EB613 is approved by the FDA, it could generate significant revenue for Entera Bio.
Analyst Recommendations
Analysts are mixed on Entera Bio. One analyst has a Buy rating on the stock, while another analyst has a Hold rating. The average analyst target price is $10.00.
